Float Short %

3.67

Margin Of Safety %

-41

Put/Call OI Ratio

0.09

EPS Next Q Diff

EPS Last/This Y

0.03

EPS This/Next Y

0.05

Price

2.62

Target Price

4.67

Analyst Recom

1.5

Performance Q

59.76

Relative Volume

1.24

Beta

1.51

Ticker: CERS

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	CERS	2.04	0.06	999.99	3887
2025-12-29	CERS	2.06	0.06	0.00	3890
2025-12-30	CERS	2.08	0.06	2.22	3896
2025-12-31	CERS	2.05	0.12	0.00	4106
2026-01-02	CERS	1.98	0.11	999.99	4408
2026-01-05	CERS	2.05	0.19	3.67	4716
2026-01-06	CERS	2.07	0.19	0.00	4728
2026-01-07	CERS	2.1	0.19	0.00	4727
2026-01-08	CERS	2.1	0.19	0.00	4727
2026-01-09	CERS	2.06	0.18	0.01	5010
2026-01-12	CERS	2.3	0.18	0.00	4988
2026-01-13	CERS	2.53	0.18	0.00	4989
2026-01-14	CERS	2.74	0.16	0.00	5471
2026-01-15	CERS	2.74	0.15	0.00	5764
2026-01-16	CERS	2.61	0.15	0.00	5864
2026-01-20	CERS	2.47	0.08	0.00	5476
2026-01-21	CERS	2.54	0.09	0.00	5478
2026-01-22	CERS	2.62	0.09	0.00	5529
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	CERS	2.03	50.0	-	-0.08
2025-12-29	CERS	2.06	50.0	-	-0.08
2025-12-30	CERS	2.08	50.0	-	-0.08
2025-12-31	CERS	2.05	50.0	-	-0.08
2026-01-02	CERS	1.98	50.0	-	-0.08
2026-01-05	CERS	2.05	50.0	-	-0.08
2026-01-06	CERS	2.08	50.0	-	-0.08
2026-01-07	CERS	2.09	50.0	-	-0.08
2026-01-08	CERS	2.10	50.0	-	-0.08
2026-01-09	CERS	2.06	50.0	-	-0.08
2026-01-12	CERS	2.30	50.0	-	-0.08
2026-01-13	CERS	2.53	50.0	-	-0.08
2026-01-14	CERS	2.75	50.0	-	-0.08
2026-01-15	CERS	2.75	50.0	-	-0.08
2026-01-16	CERS	2.61	50.0	-	-0.08
2026-01-20	CERS	2.47	50.0	-	-0.08
2026-01-21	CERS	2.54	50.0	-	-0.08
2026-01-22	CERS	2.62	50.0	-	-0.08
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	CERS	-0.32	-0.27	3.41
2025-12-29	CERS	-0.32	-0.27	3.41
2025-12-30	CERS	-0.32	-0.27	3.41
2025-12-31	CERS	-0.32	-0.27	3.41
2026-01-02	CERS	-0.32	-0.27	3.41
2026-01-05	CERS	-0.32	-0.27	3.41
2026-01-06	CERS	-0.32	-0.27	3.41
2026-01-07	CERS	-0.33	-0.27	3.41
2026-01-08	CERS	-0.33	-0.27	3.41
2026-01-09	CERS	-0.33	-0.27	3.41
2026-01-12	CERS	-0.32	-0.27	3.41
2026-01-13	CERS	-0.33	-0.27	3.67
2026-01-14	CERS	-0.33	-0.27	3.67
2026-01-15	CERS	-0.33	-0.27	3.67
2026-01-16	CERS	-0.33	-0.27	3.67
2026-01-20	CERS	-0.33	-0.60	3.67
2026-01-21	CERS	-0.33	-0.60	3.67
2026-01-22	CERS	-0.33	-0.60	3.67
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.01

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

-0.33

Institutional Transactions

-0.6

Beta

1.51

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

1.56

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

68.9

Max Drawdown 5-Year %

-85.4

Target Price

4.67

P/E

Forward P/E

PEG

P/S

2.53

P/B

8.19

P/Free Cash Flow

2960.43

EPS

-0.08

Average EPS Est. Cur. Y

-0.08

EPS Next Y. (Est.)

-0.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-8.01

Relative Volume

1.24

Return on Equity vs Sector %

-53.2

Return on Equity vs Industry %

-43.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Cerus Corporation

Sector: Healthcare

Industry: Medical Devices

Employees: 614

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

stock quote shares CERS – Cerus Corporation Stock Price stock today

news today CERS – Cerus Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch CERS – Cerus Corporation yahoo finance google finance

stock history CERS – Cerus Corporation invest stock market

stock prices CERS premarket after hours

ticker CERS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CERS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y